Premium
NIM‐R7, a novel marker for resting B1 and marginal‐zone B lymphocytes, is also expressed on activated T and B cells
Author(s) -
ManjarrezOrduño Nataly,
Parkhouse R Michael E.,
SantosArgumedo Leopoldo
Publication year - 2003
Publication title -
immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.297
H-Index - 133
eISSN - 1365-2567
pISSN - 0019-2805
DOI - 10.1046/j.1365-2567.2003.01647.x
Subject(s) - marginal zone , biology , b cell , polyclonal antibodies , b 1 cell , microbiology and biotechnology , immunology , t cell , antibody , immune system , antigen presenting cell
Summary In mice, follicular B cells have been studied in detail, while two other B‐cell subpopulations – marginal‐zone B and B1 cells – are less well understood. In this work we report the expression pattern of p58, a lymphocyte‐activation marker, recognized by rat monoclonal antibody, NIM‐R7, and present on the latter two cell subpopulations. Staining with NIM‐R7 showed that undisturbed marginal‐zone B cells, as well as peritoneal cavity and splenic B1a cells, constitutively expressed p58, whereas follicular B cells and resting T lymphocytes did not. Ontogenic analysis of different compartments showed that p58 did not appear at any stage of development, prior to the development of mature T or B2 lymphocytes. Upon polyclonal stimulation, however, p58 appeared on both T and B2 lymphocytes. Finally, ricin A‐conjugated NIM‐R7 was able to kill the BCL1 lymphoma without effect on mature resting B2 cells. Therefore, p58 may be a potential target for diagnosis or therapy of B1 and marginal‐zone B‐cell malignancies.